{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T05:39:58Z","timestamp":1784612398165,"version":"3.55.0"},"reference-count":84,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Sexual Medicine Reviews"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.sxmr.2019.12.002","type":"journal-article","created":{"date-parts":[[2020,1,23]],"date-time":"2020-01-23T23:21:17Z","timestamp":1579821677000},"page":"603-614","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Noninvasive Treatment Options for Peyronie\u2019s Disease"],"prefix":"10.1093","volume":"8","author":[{"given":"Jesse","family":"Ory","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Landan","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Langille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"10.1016\/j.sxmr.2019.12.002_bib1","doi-asserted-by":"crossref","first-page":"280","DOI":"10.21037\/tau.2016.04.05","article-title":"Peyronie's disease: A literature review on epidemiology, genetics, pathophysiology, diagnosis and work-up","volume":"5","author":"Al-Thakafi","year":"2016","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.sxmr.2019.12.002_bib2","doi-asserted-by":"crossref","first-page":"e0150157","DOI":"10.1371\/journal.pone.0150157","article-title":"The prevalence of Peyronie's disease in the United States: A Population-based study","volume":"11","author":"Stuntz","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.sxmr.2019.12.002_bib3","first-page":"745","article-title":"Peyronie's disease: AUA guideline","volume":"194","author":"Nehra","year":"2015","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2019.12.002_bib4","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1038\/sj.ijir.3901082","article-title":"Expanding the paradigm for plaque development in Peyronie's disease","volume":"15","author":"Mulhall","year":"2003","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.sxmr.2019.12.002_bib5","first-page":"311","article-title":"Fibrin deposition in Peyronie's disease plaque","volume":"157","author":"Somers","year":"2016","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2019.12.002_bib6","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/andr.12058","article-title":"Therapeutic advances in the treatment of Peyronie's disease","volume":"3","author":"Yafi","year":"2015","journal-title":"Andrology"},{"key":"10.1016\/j.sxmr.2019.12.002_bib7","first-page":"285","article-title":"Proposal: Trauma as the cause of the Peyronie's lesion","volume":"157","author":"Devine","year":"1997","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2019.12.002_bib8","first-page":"3121","article-title":"Peyronie's disease plaque calcification\u2013prevalence, time to identification, and development of a new grading classification","volume":"10","author":"Levine","year":"2013","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2019.12.002_bib9","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/bju.12634","article-title":"Minimally invasive treatment of Peyronie's disease: Evidence-based progress","volume":"114","author":"Jordan","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.sxmr.2019.12.002_bib10","first-page":"2359","article-title":"The management of Peyronie's disease: Evidence-based 2010 guidelines","volume":"7","author":"Ralph","year":"2010","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2019.12.002_bib11","first-page":"1376","article-title":"The natural history of Peyronie's disease","volume":"144","author":"Gelbard","year":"1990","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2019.12.002_bib12","first-page":"2115","article-title":"An analysis of the natural history of Peyronie's disease","volume":"175","author":"Mulhall","year":"2006","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2019.12.002_bib13","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/bju.12346","article-title":"Deformity stabilization and improvement in men with untreated Peyronie's disease","volume":"113","author":"Berookhim","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.sxmr.2019.12.002_bib14","first-page":"848","article-title":"Peyronie's disease intervention trials: Methodological challenges and issues","volume":"6","author":"Muller","year":"2009","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2019.12.002_bib15","first-page":"653","article-title":"Psychological impact of Peyronie's disease: A review","volume":"10","author":"Nelson","year":"2013","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2019.12.002_bib16","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.sxmr.2017.01.006","article-title":"Contemporary review of grafting techniques for the surgical treatment of Peyronie's disease","volume":"5","author":"Hatzichristodoulou","year":"2017","journal-title":"Sex Med Rev"},{"key":"10.1016\/j.sxmr.2019.12.002_bib17","first-page":"5653","article-title":"The Oxford 2011 levels of evidence. Oxford Centre evidence-based medicine","volume":"1","author":"Howick","year":"2011","journal-title":"Group"},{"key":"10.1016\/j.sxmr.2019.12.002_bib18","first-page":"770","article-title":"Treatment of Peyronie's disease with potassium para-aminobenzoate (potaba)","volume":"81","author":"Zarafonetis","year":"1959","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2019.12.002_bib19","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.eururo.2004.12.022","article-title":"Potassium Paraaminobenzoate (POTABATM) in the treatment of Peyronie's disease: A prospective, placebo-controlled, randomized study","volume":"47","author":"Weidner","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.sxmr.2019.12.002_bib20","doi-asserted-by":"crossref","first-page":"40","DOI":"10.5534\/wjmh.2016.34.1.40","article-title":"The efficacy of medical treatment of Peyronie's disease: Potassium para-aminobenzoate monotherapy vs. combination therapy with tamoxifen, L-carnitine, and phosphodiesterase type 5 inhibitor","volume":"34","author":"Park","year":"2016","journal-title":"World J Mens Health"},{"key":"10.1016\/j.sxmr.2019.12.002_bib21","first-page":"2967","article-title":"Acute hepatitis associated with treatment of Peyronie's disease with potassium para-aminobenzoate (potaba)","volume":"5","author":"Roy","year":"2008","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2019.12.002_bib22","first-page":"954","article-title":"Urologist practice patterns in the management of Peyronie's disease: A nationwide survey","volume":"5","author":"Shindel","year":"2008","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2019.12.002_bib23","first-page":"1398","article-title":"Comparison of vitamin E and propionyl-L-carnitine, separately or in combination, in patients with early chronic Peyronie's disease: A double-blind, placebo controlled, randomized study","volume":"178","author":"Safarinejad","year":"2007","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2019.12.002_bib24","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0090-4295(94)80155-X","article-title":"Is colchicine effective in Peyronie's disease? A pilot study","volume":"44","author":"Akkus","year":"1994","journal-title":"Urology"},{"key":"10.1016\/j.sxmr.2019.12.002_bib25","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/sj.ijir.3901185","article-title":"Therapeutic effects of colchicine in the management of Peyronie's disease: A randomized double-blind, placebo-controlled study","volume":"16","author":"Safarinejad","year":"2004","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.sxmr.2019.12.002_bib26","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/j.1464-410X.1992.tb15836.x","article-title":"The treatment of\u00a0Peyronie's disease with tamoxifen","volume":"70","author":"Ralph","year":"1992","journal-title":"Br J Urol"},{"key":"10.1016\/j.sxmr.2019.12.002_bib27","first-page":"2003","article-title":"Tamoxifen versus placebo in the treatment of Peyronie's disease","volume":"162","author":"Teloken","year":"1999","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2019.12.002_bib28","doi-asserted-by":"crossref","first-page":"4653512","DOI":"10.1155\/2017\/4653512","article-title":"Recent pathophysiological aspects of Peyronie's disease: Role of free radicals, rationale, and therapeutic implications for antioxidant treatment\u2014literature review","volume":"2017","author":"Paulis","year":"2017","journal-title":"Adv Urol"},{"key":"10.1016\/j.sxmr.2019.12.002_bib29","first-page":"1472","article-title":"The role of PDE5 inhibitors in penile septal scar remodeling: Assessment of clinical and radiological outcomes","volume":"8","author":"Chung","year":"2011","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2019.12.002_bib30","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/ijir.2010.20","article-title":"Safety and efficacy of coenzyme Q10 supplementation in early chronic Peyronie's disease: A double-blind, placebo-controlled randomized study","volume":"22","author":"Safarinejad","year":"2010","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.sxmr.2019.12.002_bib31","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1464-410X.2009.09041.x","article-title":"A\u00a0double-blind placebo-controlled study of the efficacy and safety of pentoxifylline in early chronic Peyronie's disease","volume":"106","author":"Safarinejad","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.sxmr.2019.12.002_bib32","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3109\/00365597609179649","article-title":"Induration penis plastica. Experience of treatment\u00a0with procarbazine Natulan","volume":"10","author":"Bystrom","year":"1976","journal-title":"Scand J Urol Nephrol"},{"key":"10.1016\/j.sxmr.2019.12.002_bib33","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1464-410X.1975.tb03951.x","article-title":"Treatment of Peyronie's disease with procarbazine","volume":"47","author":"Oosterlinck","year":"1975","journal-title":"Br J Urol"},{"key":"10.1016\/j.sxmr.2019.12.002_bib34","first-page":"1743","article-title":"Efficacy and safety of omega-3 for treatment of early-stage Peyronie's disease: A prospective, randomized, double-blind placebo-controlled study","volume":"6","author":"Safarinejad","year":"2009","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2019.12.002_bib35","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1365-2605.2011.01219.x","article-title":"Effectiveness of antioxidants (propolis, blueberry, vitamin E) associated with verapamil in the medical management of Peyronie's disease: a study of 151 cases","volume":"35","author":"Paulis","year":"2012","journal-title":"Int J Androl"},{"key":"10.1016\/j.sxmr.2019.12.002_bib36","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.2047-2927.2012.00007.x","article-title":"Efficacy of vitamin E\u00a0in the conservative treatment of Peyronie's disease: Legend or reality? A controlled study of 70 cases","volume":"1","author":"Paulis","year":"2013","journal-title":"Andrology"},{"key":"10.1016\/j.sxmr.2019.12.002_bib37","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2174\/1871528112666131205112432","article-title":"Long-term multimodal therapy (verapamil associated with propolis, blueberry, vitamin\u00a0E and local diclofenac) on patients with Peyronie's disease (chronic inflammation of the tunica albuginea). Results of a controlled study","volume":"12","author":"Paulis","year":"2013","journal-title":"Inflamm Allergy Drug Targets"},{"key":"10.1016\/j.sxmr.2019.12.002_bib38","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2174\/1871528111312010009","article-title":"Peironimev-Plus(R) in the treatment of chronic inflammation of tunica albuginea (Peyronie's disease). results of a controlled study","volume":"12","author":"Paulis","year":"2013","journal-title":"Inflamm Allergy Drug Targets"},{"key":"10.1016\/j.sxmr.2019.12.002_bib39","first-page":"1","article-title":"Efficacy and safety evaluation of pentoxifylline associated with other antioxidants in medical treatment of Peyronie's disease: A case-control study","volume":"8","author":"Paulis","year":"2016","journal-title":"Res Rep Urol"},{"key":"10.1016\/j.sxmr.2019.12.002_bib40","first-page":"2483","article-title":"Transdermal application of verapamil gel to the penile shaft fails to infiltrate the tunica albuginea","volume":"168","author":"Martin","year":"2002","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2019.12.002_bib41","first-page":"477","article-title":"Topical verapamil HCl, topical trifluoperazine, and topical magnesium sulfate for the treatment of Peyronie's disease--a placebo-controlled pilot study","volume":"4","author":"Fitch","year":"2007","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2019.12.002_bib42","first-page":"1081","article-title":"Comment on \u201cTopical verapamil HCL, topical trifluoroperazine, and topical magnesium sulfate for the treatment of Peyronie's disease--a placebo-controlled pilot study\u201d","volume":"4","author":"Levine","year":"2007","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2019.12.002_bib43","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1159\/000049797","article-title":"Pilot study on liposomal recombinant human superoxide dismutase for the treatment of Peyronie's disease","volume":"40","author":"Riedl","year":"2001","journal-title":"Eur Urol"},{"key":"10.1016\/j.sxmr.2019.12.002_bib44","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.eururo.2005.04.011","article-title":"Liposomal recombinant human superoxide dismutase for the treatment of Peyronie's disease: A randomized placebo-controlled double-blind prospective clinical study","volume":"48","author":"Riedl","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.sxmr.2019.12.002_bib45","first-page":"1775","article-title":"Tunica albuginea tissue analysis after electromotive drug administration","volume":"169","author":"Levine","year":"2003","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2019.12.002_bib46","first-page":"1605","article-title":"A\u00a0prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease","volume":"171","author":"Di Stasi","year":"2004","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2019.12.002_bib47","first-page":"972","article-title":"Verapamil versus saline\u00a0in\u00a0electromotive drug administration for Peyronie's disease: A\u00a0double-blind, placebo controlled trial","volume":"177","author":"Greenfield","year":"2007","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2019.12.002_bib48","first-page":"746","article-title":"Topical beta-aminopropionitrile in the treatment of Peyronie's disease","volume":"129","author":"Gelbard","year":"1983","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2019.12.002_bib49","series-title":"Campbell-walsh Urology E-Book","author":"Wein","year":"2015"},{"key":"10.1016\/j.sxmr.2019.12.002_bib50","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/bju.14602","article-title":"Penile traction therapy with the new device \u201cPenimaster PRO\u201d is effective and safe in the stable phase of Peyronie's disease: A controlled multicentre study","volume":"123","author":"Moncada","year":"2019","journal-title":"BJU Int"},{"key":"10.1016\/j.sxmr.2019.12.002_bib51","first-page":"599","article-title":"Outcomes of a novel penile traction device in men with Peyronie's disease: A randomized, single-blind, controlled trial","volume":"202","author":"Ziegelmann","year":"2019","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2019.12.002_bib52","first-page":"S86","article-title":"170 6-month outcomes of RestoreX penile traction therapy in men with Peyronie's disease: A randomized, controlled trial","volume":"16","author":"Joseph","year":"2019","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2019.12.002_bib53","first-page":"558","article-title":"Use of penile extender device in the treatment of penile curvature as a result of Peyronie's disease. Results of a phase II prospective study","volume":"6","author":"Gontero","year":"2009","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2019.12.002_bib54","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1111\/j.1464-410X.2010.09365.x","article-title":"The role of vacuum pump therapy to mechanically straighten the penis in Peyronie's disease","volume":"106","author":"Raheem","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.sxmr.2019.12.002_bib55","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/bju.13932","article-title":"Safety and effectiveness of collagenase clostridium histolyticum in the treatment of Peyronie's disease using a new modified shortened protocol","volume":"120","author":"Abdel Raheem","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.sxmr.2019.12.002_bib56","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0167-8140(99)00066-3","article-title":"Radiobiological mechanisms of anti-inflammatory radiotherapy","volume":"51","author":"Trott","year":"1999","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.sxmr.2019.12.002_bib57","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0167-8140(98)00051-6","article-title":"Indications and treatment schedules for irradiation of benign diseases: A survey","volume":"48","author":"Leer","year":"1998","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.sxmr.2019.12.002_bib58","first-page":"1435","article-title":"Radiation therapy in Peyronie's disease","volume":"9","author":"Mulhall","year":"2012","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2019.12.002_bib59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00345-016-1834-2","article-title":"Extracorporeal shock wave therapy (ESWT) in urology: a systematic review of outcome in Peyronie's disease, erectile dysfunction and chronic pelvic pain","volume":"35","author":"Fojecki","year":"2017","journal-title":"World J Urol"},{"key":"10.1016\/j.sxmr.2019.12.002_bib60","first-page":"138","article-title":"Biological effects of extracorporeal shock waves on fibroblasts. A review","volume":"1","author":"Frairia","year":"2011","journal-title":"Muscles Ligaments Tendons J"},{"key":"10.1016\/j.sxmr.2019.12.002_bib61","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.eururo.2009.05.012","article-title":"A\u00a0first prospective, randomized, double-blind, placebo-controlled clinical trial evaluating extracorporeal shock wave therapy for the treatment of Peyronie's disease","volume":"56","author":"Palmieri","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.sxmr.2019.12.002_bib62","first-page":"2815","article-title":"Extracorporeal shock wave therapy in Peyronie's disease: Results of a placebo-controlled, prospective, randomized, single-blind study","volume":"10","author":"Hatzichristodoulou","year":"2013","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2019.12.002_bib63","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1111\/j.1464-410X.2010.09331.x","article-title":"Limited shock wave therapy vs sham treatment in men with Peyronie's disease: Results of a prospective randomized controlled double-blind trial","volume":"106","author":"Chitale","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.sxmr.2019.12.002_bib64","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ijir.2016.24","article-title":"A\u00a0meta-analysis of extracorporeal shock wave therapy for Peyronie's disease","volume":"28","author":"Gao","year":"2016","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.sxmr.2019.12.002_bib65","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3109\/00365599109024539","article-title":"Regulation of the proliferation and biosynthetic activities of cultured human Peyronie's disease fibroblasts by interferons-alpha, -beta and -gamma","volume":"25","author":"Duncan","year":"1991","journal-title":"Scand J Urol Nephrol"},{"key":"10.1016\/j.sxmr.2019.12.002_bib66","first-page":"394","article-title":"Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie's disease","volume":"176","author":"Hellstrom","year":"2006","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2019.12.002_bib67","first-page":"1704","article-title":"Intralesional injection of interferon-alpha2b improves penile curvature in men with Peyronie's disease independent of plaque location","volume":"194","author":"Stewart","year":"2015","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2019.12.002_bib68","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.urology.2005.11.005","article-title":"Effect of intralesional interferon-alpha 2b combined with oral vitamin E for treatment of early stage Peyronie's disease: A randomized and prospective study","volume":"67","author":"Inal","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.sxmr.2019.12.002_bib69","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/BF00255956","article-title":"Collagenase for Peyronie's disease experimental studies","volume":"10","author":"Gelbard","year":"1982","journal-title":"Urol Res"},{"key":"10.1016\/j.sxmr.2019.12.002_bib70","first-page":"199","article-title":"Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies","volume":"190","author":"Gelbard","year":"2013","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2019.12.002_bib71","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.urology.2016.04.049","article-title":"Peyronie's disease and injectable collagenase Clostridium histolyticum: Safety, efficacy, and\u00a0improvements in subjective symptoms","volume":"94","author":"Yang","year":"2016","journal-title":"Urology"},{"key":"10.1016\/j.sxmr.2019.12.002_bib72","first-page":"1051","article-title":"Restoration of penile function and patient satisfaction with intralesional collagenase Clostridium histolyticum injection for Peyronie's disease","volume":"195","author":"Ziegelmann","year":"2016","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2019.12.002_bib73","first-page":"248","article-title":"Clinical safety and effectiveness of collagenase clostridium histolyticum injection in patients with Peyronie's disease: A phase 3 open-label study","volume":"12","author":"Levine","year":"2015","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2019.12.002_bib74","doi-asserted-by":"crossref","first-page":"639","DOI":"10.21037\/tau.2017.07.18","article-title":"Peyronie's penile plication","volume":"6","author":"Cordon","year":"2017","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.sxmr.2019.12.002_bib75","first-page":"684","article-title":"Results of SMSNA survey regarding complications following intralesional injection therapy with collagenase Clostridium histolyticum for Peyronie's disease","volume":"13","author":"Yafi","year":"2016","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2019.12.002_bib76","first-page":"1522","article-title":"Intralesional verapamil injection\u00a0for the treatment of Peyronie's disease","volume":"151","author":"Levine","year":"1994","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2019.12.002_bib77","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0090-4295(97)00700-0","article-title":"Use of intralesional verapamil to dissolve Peyronie's disease plaque: A long-term single-blind study","volume":"51","author":"Rehman","year":"1998","journal-title":"Urology"},{"key":"10.1016\/j.sxmr.2019.12.002_bib78","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s11255-009-9522-4","article-title":"Effect of intralesional verapamil for treatment of Peyronie's disease: A randomized single-blind, placebo-controlled study","volume":"41","author":"Shirazi","year":"2009","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.sxmr.2019.12.002_bib79","first-page":"3743","article-title":"Nicardipine vs. saline injection as treatment for Peyronie's disease: A prospective, randomized, single-blind trial","volume":"7","author":"Soh","year":"2010","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2019.12.002_bib80","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.eururo.2012.09.034","article-title":"Intratunical injection of human adipose tissue-derived stem cells prevents fibrosis and is associated with improved erectile function in a rat model of Peyronie's disease","volume":"63","author":"Castiglione","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.sxmr.2019.12.002_bib81","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.2047-2927.2013.00181.x","article-title":"Adipose tissue-derived stem cell therapy for prevention and treatment of erectile dysfunction in a rat model of Peyronie's disease","volume":"2","author":"Gokce","year":"2014","journal-title":"Andrology"},{"key":"10.1016\/j.sxmr.2019.12.002_bib82","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.7556\/jaoa.2015.124","article-title":"Effects of stem cell treatment in human patients with peyronie disease","volume":"115","author":"Levy","year":"2015","journal-title":"J\u00a0Am Osteopath Assoc"},{"key":"10.1016\/j.sxmr.2019.12.002_bib83","first-page":"1468","article-title":"Penile traction therapy for treatment of Peyronie's disease: A single-center pilot study","volume":"5","author":"Levine","year":"2008","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2019.12.002_bib84","first-page":"2268","article-title":"Phase 2b study of the clinical efficacy and safety of collagenase Clostridium histolyticum in patients with Peyronie disease","volume":"187","author":"Gelbard","year":"2012","journal-title":"J\u00a0Urol"}],"container-title":["Sexual Medicine Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2050052119301271?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2050052119301271?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T19:37:48Z","timestamp":1672774668000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2050052119301271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":84,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S2050052119301271"],"URL":"https:\/\/doi.org\/10.1016\/j.sxmr.2019.12.002","relation":{},"ISSN":["2050-0521"],"issn-type":[{"value":"2050-0521","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Noninvasive Treatment Options for Peyronie\u2019s Disease","name":"articletitle","label":"Article Title"},{"value":"Sexual Medicine Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.sxmr.2019.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}